Related Experiment Video
Updated: Oct 17, 2025
08:24
Conventional and Threshold-Tracking Transcranial Magnetic Stimulation Tests for Single-handed Operation
Published on: August 16, 2021
6.2K
Comparison of Compass Suprathreshold Screening Strategies
Paolo Fogagnolo1, Dario Romano1, Giovanni Montesano2,3
1Eye Clinic, ASST Santi Paolo e Carlo, Università degli Studi, 20143 Milan, Italy.
Journal of Clinical Medicine
|October 13, 2021
Summary
The Quick Suprathreshold strategy (QST) offers a significant time saving over the Standard Suprathreshold strategy (SST) for glaucoma screening, with comparable diagnostic accuracy. Both Compass (CMP) tests demonstrate high agreement with clinical diagnosis.
Area of Science:
- Ophthalmology
- Medical Technology
- Diagnostic Imaging
Background:
- Glaucoma screening programs are crucial for early detection and management.
- Compass (CMP) Standard Suprathreshold strategy (SST) assesses visual function at 52 retinal locations.
- A novel Quick Suprathreshold strategy (QST) utilizes 24 retinal locations for faster assessment.
Purpose of the Study:
- To evaluate the diagnostic performance of CMP's SST and QST against clinical diagnosis.
- To compare the test duration of SST and QST in glaucoma screening.
Main Methods:
- 63 healthy subjects and 60 glaucoma patients were recruited.
- Each participant underwent either SST or QST per eye in a randomized order.
- Results were classified as normal, suspect, or abnormal based on the SupraThreshold Response (STR) index.
Main Results:
- SST achieved 95.7% agreement with clinical diagnosis; QST achieved 95.1% agreement.
- Excluding two suspect QST results, agreement increased to 96.7%.
- QST significantly reduced test time (71 ± 41 s) compared to SST (164 ± 82 s) (p < 0.0001) in both healthy and glaucoma patient groups.
Conclusions:
- Both SST and QST demonstrate high and similar agreement with clinical diagnosis for glaucoma detection.
- QST offers a substantial time-saving advantage over SST.
- Integrating morphological analysis may further enhance the clinical utility of suprathreshold testing.
